Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–712 of 712 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Clear all
Terminated Phase 4 Interventional Results available

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

NCT03389893
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 30, 2026, 9:01 PM EDT
Active, not recruiting No phase listed Observational

Microbiome, Atopic Disease, Prematurity

NCT04835935
View directory record Official record
Conditions
Atopy, Prematurity
Interventions
microbiome pattern
Other
Lead sponsor
Sydney Leibel
Other
Eligibility
0 Days to 7 Days
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 30, 2026, 9:01 PM EDT
Terminated Not applicable Interventional

The Role of Bathing Additives in the Treatment of Pediatric Atopic Dermatitis

NCT03775590
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Water, Bleach, Acetic acid
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Months to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Rochester, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 30, 2026, 9:01 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

NCT04156191
View directory record Official record
Conditions
Atopic Dermatitis (Eczema)
Interventions
ARQ-151 cream 0.15%, ARQ-151 cream 0.05%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
3 Months to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Rancho Santa Margarita, California • Coral Gables, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 30, 2026, 9:01 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Allergic Disease Onset Prevention Study

NCT05003804
View directory record Official record
Conditions
Atopic Dermatitis, Type 1 Hypersensitivity
Interventions
STMC-103H, Placebo
Biological
Lead sponsor
Siolta Therapeutics, Inc.
Industry
Eligibility
0 Days to 14 Days
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 30, 2026, 9:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

NCT04772885
View directory record Official record
Conditions
Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions
KT-474/Placebo, KT-474
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 30, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Results available

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

NCT04804605
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
76
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 30, 2026, 9:01 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

NCT06144424
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Oral EP262, Placebo
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Miami Lakes, Florida • Plainfield, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 30, 2026, 9:01 PM EDT
Completed Phase 2 Interventional Results available

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

NCT04753034
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TER-101, Vehicle
Drug
Lead sponsor
Teres Bio, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
12
States / cities
Scottsdale, Arizona • Encinitas, California • North Miami Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 30, 2026, 9:01 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis

NCT04021862
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Bermekimab Monoclonal Antibody, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Huntington Beach, California • Coral Gables, Florida • Doral, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 30, 2026, 9:01 PM EDT
Completed Phase 1 Interventional

Evaluation of Food Hypersensitivity in Children/Adolescents With Functional Dyspepsia

NCT00328679
View directory record Official record
Conditions
Dyspepsia
Interventions
in vitro and in vivo allergy testing
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Oct 30, 2026, 9:01 PM EDT
Not listed Phase 4 Interventional

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

NCT04214197
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Top Oint
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 30, 2026, 9:01 PM EDT
Completed No phase listed Observational

Monitoring Of Scratch Via Accelerometry In Children

NCT03873220
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Wrist Actigraphy Devices, Sleep Monitor, Polysomnography, Videography
Device
Lead sponsor
Boston University
Other
Eligibility
2 Years to 11 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 30, 2026, 9:01 PM EDT
Completed Phase 2 Interventional Results available

Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)

NCT00914186
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TS022, Vehicle
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
La Jolla, California • San Diego, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 30, 2026, 9:01 PM EDT
Completed Not applicable Interventional

Brief Cognitive Behavioral Therapy to Treat Itch Rumination "Itch CBT" in Eczema

NCT04486742
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Itch CBT
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
8 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 30, 2026, 9:01 PM EDT
Completed Phase 2 Interventional Results available

Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

NCT03235024
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 30, 2026, 9:01 PM EDT